Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

A number of other brokerages have also issued reports on TTPH. BMO Capital Markets reaffirmed a “buy” rating and set a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 15th. Stifel Nicolaus lifted their price target on shares of Tetraphase Pharmaceuticals from $5.00 to $7.00 and gave the stock a “hold” rating in a research note on Thursday, March 9th.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 1.92% on Thursday, reaching $7.15. 228,398 shares of the company’s stock were exchanged. Tetraphase Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $9.93. The stock’s market capitalization is $271.39 million. The firm has a 50 day moving average of $7.48 and a 200 day moving average of $6.43.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 60.55% and a negative net margin of 1,932.24%. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.46 million. During the same period last year, the firm posted ($0.46) EPS. The company’s revenue was down 24.5% compared to the same quarter last year. Equities analysts predict that Tetraphase Pharmaceuticals will post ($2.80) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/06/tetraphase-pharmaceuticals-inc-ttph-rating-increased-to-hold-at-zacks-investment-research.html.

A number of large investors have recently bought and sold shares of TTPH. Russell Investments Group Ltd. acquired a new stake in Tetraphase Pharmaceuticals during the fourth quarter worth $156,000. Federated Investors Inc. PA increased its stake in shares of Tetraphase Pharmaceuticals by 1.0% in the fourth quarter. Federated Investors Inc. PA now owns 130,809 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 1,326 shares in the last quarter. State Street Corp increased its stake in shares of Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock valued at $2,864,000 after buying an additional 11,391 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 15,931 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Tetraphase Pharmaceuticals by 580.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 226,222 shares of the biopharmaceutical company’s stock valued at $912,000 after buying an additional 192,972 shares in the last quarter. Hedge funds and other institutional investors own 47.77% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.